Close

Drug Research

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471

Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is...

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

Samsung Biologics, one of the world’s leading contract development and manufacturing organization (CDMO), signed a strategic partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell...

LGM Pharma launches standalone analytical services for drug developers and manufacturers

LGM Pharma announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies. The company, which already conducts analytical services as part of its integrated contract...

Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC

Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce the signature of a manufacturing services agreement with Exelixis, a commercially successful, oncology-focused US biotechnology company, for the cGMP clinical production of...

I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics,  announced multiple advancements in its 4-1BB bispecific antibody portfolio. Stimulation of 4-1BB is a promising therapeutic strategy for improving the current immunotherapy for cancers....

Batavia to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine

Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the...

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline. The collaborations with Immorna, an...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read